Votrient (geneically known as pazopanib) is an oral medication indicated to treat certain types of cancer. It is indicated for the treatment of advanced renal cell carcinoma (RCC), a type of kidney cancer, and advanced soft tissue sarcoma (STS), a type of cancer that affects the body’s connective tissues, such as muscles, tendons, and cartilage.
Votrient is a type of targeted cancer drug called a tyrosine kinase inhibitor (TKI). Tyrosine kinases are proteins that help to control the growth and division of cells. Votrient blocks several tyrosine kinases on the surface of cancer cells, as well as targets within the cell. By blocking these signals, Votrient can help slow or stop the growth of cancer cells. Additionally, Votrient is thought to work, in part, by blocking the growth of new blood vessels that support tumor growth.
Votrient is typically prescribed to patients who have already received prior chemotherapy. It is approved for the treatment of advanced renal cell carcinoma (kidney cancer) and soft tissue sarcoma. It should be taken exactly as prescribed by the healthcare provider.
REVIEWS